Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Adult patients affected by stage IIB, IIC, III and IV melanoma who start systemic therapy with immune-checkpoint inhibitors.
Signature of the patient consent to the study.

Patients aged below 18 years of age.
Patients who are unable to express consent to the study.
Patients with a diagnosis of chronic joint diseases: inflammatory arthritis, arthrosis, microcrystalline arthritis, septic arthritis etc.
Systemic diseases with likely joint involvement (inflammatory bowel disease, etc.)
Previous treatments with immune-checkpoint inhibitors or previous adjuvant therapy with immune-checkpoint inhibitors.

Clinical and Ultrasound Incidence of Rheumatologic Immune Related Adverse Events in Stage IIB-IV Melanoma Patients